BSF Enterprise PLC (LSE:BSFA) has signed heads of terms for a worldwide commercialisation and supply agreement covering its proprietary ETSYL bioactive peptide, opening a potential new route to revenue across luxury skincare and the wider cosmetics market.
The agreement with SCHAKAU Managementberatung GmbH gives SCHAKAU exclusive global rights to ETSYL for cosmetic applications for an initial 10-year period, subject to meeting agreed sales volume targets.
SCHAKAU plans to use ETSYL as the principal active ingredient in its ultra-luxury HANDS OF GOD skincare brand while also pursuing opportunities to license the peptide to other businesses in the cosmetics sector.
Under the proposed arrangement, SCHAKAU will fund approximately €300,000 of expenditure covering clinical validation, regulatory activities and brand development. This allows BSF to advance commercialisation without directly funding those elements of the programme.
Importantly, BSF will retain full ownership of the intellectual property associated with ETSYL. Its wholly owned subsidiary, 3D Bio-tissues, is also expected to generate near-term revenue from supplying the raw material required for commercial products.
The agreement provides an additional potential income stream through third-party licensing. Revenue generated from licensing ETSYL to other cosmetics businesses will be divided equally between BSF and SCHAKAU.
The structure gives BSF a relatively capital-light route for commercialising its peptide technology while retaining ownership of the underlying intellectual property. Successful development of the HANDS OF GOD brand or additional B2B licensing agreements could provide further evidence that the group’s scientific platform can generate commercial opportunities beyond its core biotechnology activities.
However, the 10-year exclusivity remains dependent on sales volumes, making commercial adoption an important measure of the agreement’s longer-term value.
BSF’s wider outlook also remains constrained by persistent losses and negative cash flow. Technical indicators are similarly weak, with the shares trading below key moving averages and momentum remaining negative.
Valuation provides limited support while the company remains loss-making, and the absence of a dividend means investors remain primarily dependent on future commercial progress and execution.
More about BSF Enterprise PLC
BSF Enterprise PLC is a biotechnology company developing tissue engineering, lab-grown materials and bioactive technologies through its wholly owned subsidiary 3D Bio-tissues Ltd.
The group develops proprietary bioactive peptides and tissue technologies with potential applications across cosmetics, skincare and advanced materials, including alternatives to conventional leather.
Its commercial strategy includes developing and licensing technologies from its scientific platform while pursuing partnerships capable of bringing those technologies into end markets. BSF Enterprise shares trade on the London Stock Exchange under the symbol BSFA.
Leave a Reply